title: Comparison of efficacy and safety between liposome-paclitaxel injection plus carboplatin and paclitaxel plus carboplatin as first line treatment in advanced non-small cell lung cancer.
abstract: OBJECTIVE
  To compare the efficacy and safety between liposome-paclitaxel plus carboplatin (LPC) and paclitaxel plus carboplatin (PC) as first-line treatment for advanced non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Totally 54 chemotherapy-naive NSCLC patients were equally and randomly assigned into LPC group and PC group. Liposome-paclitaxel was injected on D1 at a dosage of 175 mg/m(2); the same dose and administration with paclitaxel injection in the PC group for a maximum of 2 cycles. The efficacy and adverse reactions after 2 cycles of chemotherapy were compared between these two groups.
  
  
  RESULTS
  The overall response rate (CR+PR) was 44.4% in the LPC group and 33.3% in the PC group after 2 cycles of chemotherapy respectively (P=0.577). In the LPC group and PC group, the incidences of myelodepression was 81.5% and 63.0%, respectively (P=0.080), gastrointestinal toxicity was 96.3% and 77.8% respectively (P=0.100), and allergic reactions was 0 and 11.1%, respectively (P=0.000). The median time to progression was 6 months and 5 months, respectively (P=0.420).
  
  
  CONCLUSIONS
  LPC group has the same efficacy with PC group and less adverse reactions than PC group.
authors.affiliation: Department of Medical Oncology,Cancer Institute & Hospital,CAMS and PUMC,Beijing 100021,China.
authors.forename: Hong-yu
authors.initials: HY
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology,Cancer Institute & Hospital,CAMS and PUMC,Beijing 100021,China.
authors.forename: Xiang-ru
authors.initials: XR
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D016190:Carboplatin / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008081:Liposomes; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D008081:Liposomes; D016190:Carboplatin; D017239:Paclitaxel